Transmission of coronavirus by nebulizer: a serious, underappreciated risk
- PMID: 32392488
- PMCID: PMC7124163
- DOI: 10.1503/cmaj.75066
Transmission of coronavirus by nebulizer: a serious, underappreciated risk
Conflict of interest statement
Competing interests: Michael Newhouse is employed by InspiRx Pharmaceuticals Inc. as the Chief Medical Officer and has patents through InspiRx Pharmaceuticals Inc. (6,470.882; 8,119,016; D 689,602; D 685,085; and D 686725; Pending: US 2012/0318261 and 2012/0318265). No other competing interests were declared.
Comment on
-
Communication, transparency key as Canada faces new coronavirus threat.CMAJ. 2020 Feb 18;192(7):E171-E172. doi: 10.1503/cmaj.1095846. CMAJ. 2020. PMID: 32071113 Free PMC article. No abstract available.
References
-
- Prevention and control of influenza during a pandemic for all healthcare settings. Annex F. Ottawa: Public Health Agency of Canada; 2011. Available: www.phac-aspc.gc.ca/cpip-pclcpi/assets/pdf/ann-f-eng.pdf (accessed 2020 Mar. 1).
-
- Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2006;(2):CD000052. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources